Lexaria Bioscien Stock Price, News & Analysis

Lexaria Bioscience Corp. (NASDAQ:LEXX, LEXXW) has launched study DIAB-A22-1 to explore the therapeutic potential of its DehydraTECH-processed CBD for diabetes. The research involves 32 male Zucker rats over 56 days to assess weight gain, blood glucose, cholesterol, and triglyceride levels. Lexaria's technology has previously shown promise in hypertension. The diabetes market is significant, with global device and drug markets estimated at $26.7 billion and $63.1 billion, respectively. Results from the study are expected in early January 2023.

Lexaria Bioscience Corp. (Nasdaq:LEXX, LEXXW) announced IRB approval for its upcoming human clinical study NIC-H22-1, comparing its DehydraTECH-nicotine pouch to leading brands ON! and Zyn. The 36-person study will evaluate various metrics, including nicotine absorption and user experience. Previous studies indicate DehydraTECH technology may enhance nicotine delivery, achieving up to 20x faster absorption. With the oral nicotine pouch market projected to grow from $2.33 billion in 2020 to $21.84 billion by 2027, Lexaria aims to capitalize on this trend with its patented technology.

Lexaria Bioscience Corp. (Nasdaq: LEXX, LEXXW) announced positive results from its human clinical study HYPER-H21-4, demonstrating significant and sustained blood pressure (BP) reductions in hypertensive patients using its DehydraTECH-CBD formulation. Key findings include an average systolic BP reduction of up to 7.01 mmHg over five weeks, with no serious adverse events reported. The study suggests potential additive BP lowering effects for patients on standard medications. Lexaria plans to advance into a Phase Ib clinical study with the U.S. FDA.

Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) announced the appointment of Dr. Catherine Turkel to its board of directors, enhancing its leadership at a pivotal time. Dr. Turkel brings over 20 years of experience in the pharma and biotech sector, notably leading global drug development programs. Her expertise in regulatory strategy and commercial planning, particularly with Allergan's BOTOX program, is expected to advance Lexaria's DehydraTECH technology, which enhances the delivery of active pharmaceutical ingredients. Lexaria is positioned for continued growth following a successful pre-IND meeting with the FDA.

Lexaria Bioscience Corp. (Nasdaq:LEXX, LEXXW) announced the granting of its 27th international patent in Mexico under registration #390001. This patent is part of Lexaria's third patent family, covering Stable Ready-to-Drink Beverage Compositions Comprising Lipophilic Active Agents, which has also received recognition in Australia, India, and Japan. The patent allows the use of DehydraTECH-processed non-psychoactive cannabinoids to treat various disorders, including hypertension and neurological diseases. Lexaria continues its regulatory pursuit for DehydraTECH-CBD in pharmaceutical applications.

Lexaria Bioscience Corp. (Nasdaq:LEXX, LEXXW) recently provided insights on third-party valuation methods for biotech firms. Highlighting the lengthy and costly drug development process, the company noted that its DehydraTECH-CBD program is advancing through FDA's clinical research phase. Valuation metrics show significant potential for drugs in different clinical trial phases, with estimated valuations of $88 million, $248 million, and $1.12 billion at the start of Phase I, II, and III, respectively. Lexaria indicated that pursuing the FDA's 505(b)(2) regulatory pathway could enhance approval prospects.

Lexaria Bioscience Corp. (NASDAQ:LEXX, LEXXW) announced the successful completion of dosing in its clinical hypertension study, HYPER-H21-4, involving 64 patients. The study was randomized, double-blind, and placebo-controlled, aimed at assessing the safety and efficacy of DehydraTECH-CBD. Notably, no serious adverse events were reported, marking a significant safety milestone. The findings are anticipated to support an IND application to the FDA for further clinical testing. Secondary outcomes will include various cardiovascular health metrics, brain function, and overall health assessments, with data analyses expected to begin in September.

Lexaria Bioscience Corp. has issued a five-year, non-exclusive DehydraTECH license to AnodGen Bioceuticals for the European, Australian, and New Zealand markets. The license allows AnodGen to manufacture and distribute cannabinoid active pharmaceutical ingredient powders and mandates royalty payments to Lexaria for all sales. This partnership aims to enhance bioavailability and absorption of cannabinoid products. AnodGen plans to operationalize its facility in Ireland by the end of 2022, aiming for significant growth in the pharmaceutical sector.

Lexaria Bioscience Corp. (Nasdaq:LEXX, LEXXW) has filed a pre-Investigational New Drug (IND) meeting request with the FDA, successfully initiating communication regarding its DehydraTECH-CBD for hypertension treatment. The FDA confirmed receipt and set a target date of July 30, 2022 for follow-up, contingent on meeting specific conditions. This meeting aims to clarify Lexaria's IND-enabling development program ahead of a full IND application expected later in 2022 or early 2023. The hypertension market, valued at $28 billion, presents significant potential for Lexaria's innovative drug delivery technology.